98 related articles for article (PubMed ID: 1363282)
1. PC-10 antibody to proliferating cell nuclear antigen (PCNA) is not related to prognosis in human breast carcinoma.
Gasparini G; Meli S; Pozza F; Cazzavillan S; Bevilacqua P
Growth Regul; 1992 Dec; 2(4):145-50. PubMed ID: 1363282
[TBL] [Abstract][Full Text] [Related]
2. Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has prognostic impact in archival paraffin-embedded node-negative breast cancer.
Siitonen SM; Kallioniemi OP; Isola JJ
Am J Pathol; 1993 Apr; 142(4):1081-9. PubMed ID: 7682759
[TBL] [Abstract][Full Text] [Related]
3. Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in axillary lymph node negative breast cancer.
Aaltomaa S; Lipponen P; Syrjänen K
Anticancer Res; 1993; 13(2):533-8. PubMed ID: 8100128
[TBL] [Abstract][Full Text] [Related]
4. Proliferative activity is a significant prognostic factor in male breast carcinoma.
Pich A; Margaria E; Chiusa L
Am J Pathol; 1994 Aug; 145(2):481-9. PubMed ID: 7519830
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinoma breast.
Aziz SA; Pervez S; Khan SM; Kayani N; Nasir MI
J Coll Physicians Surg Pak; 2005 Apr; 15(4):225-9. PubMed ID: 15857596
[TBL] [Abstract][Full Text] [Related]
6. Correlation of proliferative index (PCNA reactivity and Ki-67 reactivity) in primary breast carcinoma with hormone status, lymph node status, and disease-free survival.
Magno WB; Hirschfield L; Bhuiya T; Harrison G; Mir R
Conn Med; 1992 Dec; 56(12):667-9. PubMed ID: 1363223
[TBL] [Abstract][Full Text] [Related]
7. Minimal breast cancer: analysis of proliferative activity using a monoclonal antibody to proliferating cell nuclear antigen (PCNA) and its relationship to histological grade and prognosis.
Lanzafame S; Magro G; Broggi B
Pathologica; 1994 Apr; 86(2):150-6. PubMed ID: 7936757
[TBL] [Abstract][Full Text] [Related]
8. Proliferating cell nuclear antigen immunostaining in breast cancer and its relation to prognosis.
Narita T; Funahashi H; Satoh Y; Takagi H
Jpn J Clin Oncol; 1993 Feb; 23(1):20-5. PubMed ID: 8096256
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinomas: comparison with clinical and pathologic variables.
Frierson HF
Mod Pathol; 1993 May; 6(3):290-4. PubMed ID: 8102204
[TBL] [Abstract][Full Text] [Related]
10. Rapid and prognostically valid quantification of immunohistochemical reactions by immunohistometry of the most positive tumour focus. A prospective follow-up study on breast cancer using antibodies against MIB-1, PCNA, ER, and PR.
Biesterfeld S; Klüppel D; Koch R; Schneider S; Steinhagen G; Mihalcea AM; Schröder W
J Pathol; 1998 May; 185(1):25-31. PubMed ID: 9713356
[TBL] [Abstract][Full Text] [Related]
11. Ampullary carcinoma: prognostic significance of ploidy, cell-cycle analysis and proliferating cell nuclear antigen (PCNA).
Crucitti A; Masetti R; Breccia C; Coppola R; Magistrelli P; Nuzzo G; Maggiano N; Picciocchi A
Hepatogastroenterology; 1999; 46(26):1187-91. PubMed ID: 10370689
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of cell proliferation in breast cancer as determined by proliferating cell nuclear antigen (PCNA) immunostaining.
Aaltomaa S; Lipponen P; Syrjänen K
Anticancer Res; 1992; 12(4):1281-6. PubMed ID: 1380227
[TBL] [Abstract][Full Text] [Related]
13. Localization of p53 and proliferating cell nuclear antigen in fine-needle aspirates of benign and primary malignant tumors of the human breast: an immunocytochemical study using supersensitive monoclonal antibodies and the biotin-streptavidin-amplified method.
Alexiev BA
Diagn Cytopathol; 1996 Nov; 15(4):277-81. PubMed ID: 8982580
[TBL] [Abstract][Full Text] [Related]
14. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic study associated with long-term survival in Japanese patients with node-negative breast cancer.
Kato T; Kimura T; Miyakawa R; Fujii A; Yamamoto K; Kameoka S; Nishikawa T; Kasajima T
Br J Cancer; 2000 Jan; 82(2):404-11. PubMed ID: 10646896
[TBL] [Abstract][Full Text] [Related]
16. C-erbB-2 and PCNA as prognostic indicators of long-term survival in breast cancer.
Kato T; Kameoka S; Kimura T; Nishikawa T; Kobayashi M
Anticancer Res; 2002; 22(2B):1097-103. PubMed ID: 12168907
[TBL] [Abstract][Full Text] [Related]
17. Proliferating cell nuclear antigen (PCNA), immunostaining and flow cytometric DNA analysis of renal cell carcinoma.
Tanioka F; Hiroi M; Yamane T; Hara H
Zentralbl Pathol; 1993 Aug; 139(3):185-93. PubMed ID: 8105885
[TBL] [Abstract][Full Text] [Related]
18. Proliferating cell nuclear antigen immunostaining in breast carcinoma and its relationship to clinical and pathological variables.
Agarwal S; Jain R; Rusia U; Gupta RL
Indian J Pathol Microbiol; 1997 Jan; 40(1):11-6. PubMed ID: 9145605
[TBL] [Abstract][Full Text] [Related]
19. Optimization of immunohistochemical staining of proliferating cells in paraffin sections of breast carcinoma using antibodies to proliferating cell nuclear antigen and the Ki-67 antigen.
Yu CC; Dublin EA; Camplejohn RS; Levison DA
Anal Cell Pathol; 1995 Jul; 9(1):45-52. PubMed ID: 7577754
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical assessment of proliferation rate of breast carcinoma cells using Ki-67, MIB-1 and anti-PCNA monoclonal antibodies.
Markiewski M; Domagała W
Pol J Pathol; 1996; 47(4):189-94. PubMed ID: 9097711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
